Advanced Search

Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2009 July-August;75(7-8) > Minerva Anestesiologica 2009 July-August;75(7-8):417-26



A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care

Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,036

Frequency: Monthly

ISSN 0375-9393

Online ISSN 1827-1596


Minerva Anestesiologica 2009 July-August;75(7-8):417-26


Effects of recombinant human activated protein C on the fibrinolytic system of patients undergoing conventional or tight glycemic control

Polli F. 1, Savioli M. 2, Cugno M. 3, Taccone P. 2, Bellani G. 4,5, Spanu P. 6, Pesenti A. 4,5, Iapichino G. 1,6, Gattinoni L.1,2

1 Institute of Anesthesia and Intensive Care, University of Milan, Milan, Italy;
2 Unit of Anesthesia and Intensive Care, Department of Anesthesia, Intensive and Subintensive Care and Pain Therapy, IRCCS Foundation, Mangiagalli, Regina Elena Polyclinic Hospital of Milan, Milan, Italy;
3 Department of Internal Medicine, University of Milan, Milan, Italy;
4 Department of Perioperatory Medicine and Intensive Care, San Gerardo General Hospital of Monza, Monza, Italy;
5 Department of Experimental Medicine, University of Milan-Bicocca, Milan, Italy;
6 Unit of Anesthesia and Intensive Care, San Paolo University General Hospital, Milan, Italy

Aim. Recombinant human activated protein C (rh-APC) and tight glycemic control (TGC) have been shown to reduce mortality in septic patients. Both interventions can reduce the plasma concentration and/or activity of the most powerful suppressor of fibrinolysis, plasminogen activator inhibitor-1 (PAI-1). Our aim was to evaluate the effects on the fibrinolytic system after the administration of rh-APC in septic patients undergoing conventional or TGC.
Methods. Posthoc analysis of data was collected from 90 patients with severe sepsis/septic shock, randomized to either conventional or TGC groups. Independent of these treatments, patients with at least two organ dysfunctions simultaneously received rh-APC. Plasma levels of multiple biochemical markers for fibrinolysis, coagulation, and inflammation were determined every day for the 1st week and then on study days 9, 11, 13, 18, 23, and 28. Clinical data and sepsis-related organ failure assessment (SOFA) scores were also recorded.
Results. Patients who had received rh-APC exhibited significantly more impairments in fibrinolysis at baseline (PAI-1 activity 49.76 [24.61-71.82] vs 21.92 [6.47-55-83] IU/mL, P=0.03). The reductions in plasma PAI-1 activity over time associated with rh-APC treatment were different according to whether the treatment was administered to patients undergoing conventional or TGC (P=0.01). However, the most prominent reductions were in patients undergoing conventional glycemic control. Significant interactions between the two study interventions were also found for PAI-1 concentration (P<0.001), C-reactive protein (P=0.02), and interleukin-6 levels (P<0.001).
Conclusion. Both rh-APC and TGC appear to improve fibrinolysis in septic patients. The reduction in the impairment of fibrinolysis associated with rh-APC treatment seems greater in patients undergoing conventional glycemic control than in those undergoing TGC.

language: English


top of page